CJC-1295

Safety Profile of CJC-1295

Evidence Limitation Notice: The available evidence for CJC-1295 safety is limited, consisting primarily of narrative reviews and one terminated clinical trial. No completed randomized controlled trials with comprehensive safety data were identified.

Known Side Effects

The evidence base for CJC-1295 side effects is thin. Available literature consists mainly of review articles that do not provide specific adverse event data from controlled studies. The single identified clinical trial (NCT00267527) investigating CJC-1295 in HIV patients with visceral obesity was terminated, and safety outcomes from this study are not available in the provided evidence.

Contraindications

No specific contraindications for CJC-1295 are established in the available evidence. This represents a significant knowledge gap given the compound's mechanism of action on the growth hormone-IGF-1 axis.

Drug Interactions

The provided evidence does not contain information about drug interactions with CJC-1295. This lack of data is concerning given that the compound affects hormone pathways that could potentially interact with other medications.

Populations That Should Exercise Caution

While specific safety data is lacking, the following populations may be at increased risk based on CJC-1295's mechanism of action on growth hormone pathways:

• Individuals with active malignancies (theoretical concern due to IGF-1's growth-promoting effects)
• Patients with diabetes (potential effects on glucose metabolism)
• Individuals with cardiovascular disease
• Pregnant or breastfeeding women
• Children and adolescents

Important Note: These precautions are based on theoretical concerns related to growth hormone pathway modulation rather than specific clinical evidence for CJC-1295.

Regulatory Status and Safety Concerns

The available literature indicates that CJC-1295 is used in recreational and professional sports settings, often without medical supervision. Several reviews emphasize safety concerns related to the use of unapproved peptide therapies and highlight the need for more rigorous clinical evidence.

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Anyone considering CJC-1295 should consult with a qualified healthcare provider to discuss potential risks and benefits based on their individual medical history and circumstances.

Critical Gap: The termination of the only identified clinical trial and the lack of published safety data represent significant limitations in our understanding of CJC-1295's safety profile. More research is needed to establish appropriate safety guidelines for this compound.